Assignee
IMMUNOGEN INC
US·202 granted patents·128 pending applications·13,364 citations·filing 1992–2025
Top patents by PatentIndex Score
330 records- 0199US7851432B2Cytotoxic agents comprising new maytansinoidsIMMUNOGEN INC·Filed 2007·Granted Dec 14, 2010·54 cites·33 claims
- 0299US7601354B2Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agentsIMMUNOGEN INC·Filed 2006·Granted Oct 13, 2009·161 cites·17 claims
- 0399US7368565B2Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agentsIMMUNOGEN INC·Filed 2002·Granted May 6, 2008·239 cites·17 claims
- 0499US7303749B1Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agentsIMMUNOGEN INC·Filed 2000·Granted Dec 4, 2007·226 cites·16 claims
- 0599US7276497B2Cytotoxic agents comprising new maytansinoidsIMMUNOGEN INC·Filed 2004·Granted Oct 2, 2007·402 cites·31 claims
- 0699US7276499B2Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2006·Granted Oct 2, 2007·58 cites·21 claims
- 0799US6716821B2Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the sameIMMUNOGEN INC·Filed 2001·Granted Apr 6, 2004·359 cites·92 claims
- 0899US6630579B2Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic useIMMUNOGEN INC·Filed 2000·Granted Oct 7, 2003·547 cites·16 claims
- 0999US6596757B1Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic useIMMUNOGEN INC·Filed 2002·Granted Jul 22, 2003·165 cites·48 claims
- 1099US6534660B1CC-1065 analog synthesisIMMUNOGEN INC·Filed 2002·Granted Mar 18, 2003·168 cites·9 claims
- 1199US6441163B1Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agentsIMMUNOGEN INC·Filed 2001·Granted Aug 27, 2002·690 cites·27 claims
- 1299US6436931B1Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2002·Granted Aug 20, 2002·184 cites·24 claims
- 1399US6340701B1Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2000·Granted Jan 22, 2002·271 cites·24 claims
- 1499US6333410B1Process for the preparation and purification of thiol-containing maytansinoidsIMMUNOGEN INC·Filed 2000·Granted Dec 25, 2001·412 cites·34 claims
- 1599US5846545ATargeted delivery of cyclopropylbenzindole-containing cytotoxic drugsIMMUNOGEN INC·Filed 1995·Granted Dec 8, 1998·531 cites·57 claims
- 1699US5585499ACyclopropylbenzindole-containing cytotoxic drugsIMMUNOGEN INC·Filed 1995·Granted Dec 17, 1996·541 cites·8 claims
- 1799US5475092ACell binding agent conjugates of analogues and derivatives of CC-1065IMMUNOGEN INC·Filed 1994·Granted Dec 12, 1995·668 cites·8 claims
- 1898US9434748B2Cytotoxic benzodiazepine derivativesIMMUNOGEN INC·Filed 2015·Granted Sep 6, 2016·15 cites·25 claims
- 1998US7989598B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesIMMUNOGEN INC·Filed 2007·Granted Aug 2, 2011·46 cites·53 claims
- 2098US7557189B2Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the sameIMMUNOGEN INC·Filed 2003·Granted Jul 7, 2009·109 cites·44 claims
- 2198US7473796B2Cytotoxic agents comprising new maytansinoidsIMMUNOGEN INC·Filed 2007·Granted Jan 6, 2009·55 cites·13 claims
- 2298US7388026B2Prodrugs of CC-1065 analogsIMMUNOGEN INC·Filed 2005·Granted Jun 17, 2008·68 cites·6 claims
- 2398US7342110B2Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the sameIMMUNOGEN INC·Filed 2006·Granted Mar 11, 2008·82 cites·10 claims
- 2498US7301019B2Method for the preparation of maytansinoid estersIMMUNOGEN INC·Filed 2006·Granted Nov 27, 2007·41 cites·27 claims
- 2598US7097840B2Methods of treatment using anti-ErbB antibody-maytansinoid conjugatesIMMUNOGEN INC·Filed 2001·Granted Aug 29, 2006·266 cites·44 claims
- 2698US6913748B2Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugsIMMUNOGEN INC·Filed 2003·Granted Jul 5, 2005·209 cites·34 claims
- 2798US6756397B2Prodrugs of CC-1065 analogsIMMUNOGEN INC·Filed 2002·Granted Jun 29, 2004·144 cites·5 claims
- 2898US6706708B2Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2002·Granted Mar 16, 2004·71 cites·12 claims
- 2998US6586618B1CC-1065 analog synthesisIMMUNOGEN INC·Filed 2002·Granted Jul 1, 2003·125 cites·2 claims
- 3098US5416064ACytotoxic agents comprising maytansinoids and their therapeutic useIMMUNOGEN INC·Filed 1992·Granted May 16, 1995·1.3k cites·20 claims
- 3198US5208020ACytotoxic agents comprising maytansinoids and their therapeutic useIMMUNOGEN INC·Filed 1992·Granted May 4, 1993·2.4k cites·18 claims
- 3297US10752683B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2019·Granted Aug 25, 2020·13 cites·31 claims
- 3397US9670279B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted Jun 6, 2017·26 cites·118 claims
- 3497US9359442B2Anti-CD33 antibodies and methods for treatment of acute myeloid leukemia using the sameIMMUNOGEN INC·Filed 2014·Granted Jun 7, 2016·29 cites·10 claims
- 3597US9169272B2Cytotoxic benzodiazepine derivativesIMMUNOGEN INC·Filed 2014·Granted Oct 27, 2015·19 cites·16 claims
- 3697US9133275B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2013·Granted Sep 15, 2015·45 cites·44 claims
- 3797US7655661B2Prodrugs of CC-1065 analogsIMMUNOGEN INC·Filed 2008·Granted Feb 2, 2010·35 cites·7 claims
- 3897US7655660B2Prodrugs of CC-1065 analogsIMMUNOGEN INC·Filed 2007·Granted Feb 2, 2010·39 cites·7 claims
- 3997US7411063B2Process for preparation of maytansinolIMMUNOGEN INC·Filed 2006·Granted Aug 12, 2008·31 cites·48 claims
- 4097US7049316B2Prodrugs of CC-1065 analogsIMMUNOGEN INC·Filed 2003·Granted May 23, 2006·77 cites·9 claims
- 4197US5639641AResurfacing of rodent antibodiesIMMUNOGEN INC·Filed 1992·Granted Jun 17, 1997·870 cites·16 claims
- 4296US10844135B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making saidIMMUNOGEN INC·Filed 2017·Granted Nov 24, 2020·7 cites·35 claims
- 4396US10208127B2Benzodiazepine derivativesIMMUNOGEN INC·Filed 2018·Granted Feb 19, 2019·6 cites·6 claims
- 4496US10179818B2Cytotoxic benzodiazepine derivativesIMMUNOGEN INC·Filed 2017·Granted Jan 15, 2019·6 cites·24 claims
- 4596US9868791B2Methods of preparation of conjugatesIMMUNOGEN INC·Filed 2016·Granted Jan 16, 2018·8 cites·12 claims
- 4696US9840564B2Cytotoxic benzodiazepine derivativesIMMUNOGEN INC·Filed 2016·Granted Dec 12, 2017·7 cites·3 claims
- 4796US9670280B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted Jun 6, 2017·19 cites·74 claims
- 4896US9670278B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted Jun 6, 2017·18 cites·104 claims
- 4996US9657100B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted May 23, 2017·16 cites·40 claims
- 5096US9598490B2Folate receptor 1 antibodies and immunoconjugates and uses thereofIMMUNOGEN INC·Filed 2015·Granted Mar 21, 2017·18 cites·40 claims
Showing the top 50 of 330 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when IMMUNOGEN INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →